Vaxcyte NasdaqGS:PCVX 주식 보고서 Vaxcyte, Inc.
NasdaqGS:PCVX 주식 보고서
PCVX 주식 개요 임상 단계의 생명공학 백신 회사인 박사이츠는 세균성 전염병을 예방하거나 치료하는 새로운 단백질 백신을 개발하는 회사입니다.
보상 위험 분석 + 1 더 많은 위험
모든 위험 점검 보기 가격 내역 및 성능
다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Vaxcyte 과거 주가 현재 주가 US$99.38 52주 최고치 US$121.06 52주 최저치 US$48.24 베타 1.01 11개월 변경 -13.14% 3개월 변경 사항 29.15% 1년 변경 사항 100.57% 33년 변화 285.19% 5년 변화 n/a IPO 이후 변화 280.04%
최근 뉴스 및 업데이트 더 많은 업데이트 보기
Co-Founder notifies of intention to sell stock Nov 04
Insufficient new directors Nov 01
President & CFO notifies of intention to sell stock Oct 20
Co-Founder notifies of intention to sell stock Oct 03
Executive VP & COO notifies of intention to sell stock Sep 18
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy Sep 06 Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion. Sep 06
Executive VP & COO notifies of intention to sell stock Sep 05 Vaxcyte, Inc. has filed a Follow-on Equity Offering. Sep 04
New major risk - Revenue and earnings growth Sep 03
Price target increased by 27% to US$131 Sep 03
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older Sep 03
We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate Aug 24
President & CFO notifies of intention to sell stock Aug 21
President & CFO notifies of intention to sell stock Jul 21
Vaxcyte Appoints John Furey to Board of Directors Jul 02
President & CFO notifies of intention to sell stock Jun 20
Independent Director notifies of intention to sell stock Jun 06
President & CFO notifies of intention to sell stock May 22
New major risk - Revenue and earnings growth May 10
Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry? May 10
President & CFO notifies of intention to sell stock Apr 22
Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024 Apr 16
President & CFO notifies of intention to sell stock Mar 20
New major risk - Revenue and earnings growth Mar 12
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants Mar 05
New major risk - Revenue and earnings growth Feb 23
President & CFO notifies of intention to sell stock Feb 22
Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 16 Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million. Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.
President & CFO notifies of intention to sell stock Jan 21
Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer Jan 17
Price target increased by 7.8% to US$71.14 Jan 06
Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise Jan 05
Co-Founder notifies of intention to sell stock Dec 29
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans Dec 27
Senior VP notifies of intention to sell stock Dec 10
Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases Dec 05
Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors Nov 29
President & CFO notifies of intention to sell stock Nov 24
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Nov 10
President & CFO notifies of intention to sell stock Oct 21
Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Oct 20
Co-Founder notifies of intention to sell stock Sep 27
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely Sep 12
Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation May 30
Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 17
President exercised options to buy US$1.1m worth of stock. Jan 08
Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults Jan 06
Executive VP & COO exercised options to buy US$5.1m worth of stock. Dec 30
We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth Dec 22
Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023 Dec 13
Independent Director exercised options and sold US$131k worth of stock Nov 16
High number of new directors Nov 16
Price target increased to US$60.50 Nov 12
Independent Director exercised options and sold US$147k worth of stock Oct 28
Price target increased to US$56.00 Oct 27
Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64 Oct 25
Co-Founder & VP of Research notifies of intention to sell stock Oct 15
Vaxcyte, Inc. Announces Executive Appointments Oct 12
Vaxcyte appoints new CBO, CMO Oct 11
Co-Founder notifies of intention to sell stock Sep 19
Co-Founder & VP of Research notifies of intention to sell stock Sep 10
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older Sep 07
Co-Founder notifies of intention to sell stock Aug 19
Co-Founder & VP of Research notifies of intention to sell stock Aug 08
Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs Aug 06
Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs Aug 05
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans Aug 05
Insider notifies of intention to sell stock Jul 31
Co-Founder notifies of intention to sell stock Jul 21
President & CFO notifies of intention to sell stock Jul 14
Vaxcyte, Inc. Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of Vax-24 in Adults Jul 13
Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate Jul 12
Executive VP & COO notifies of intention to sell stock Jul 08
Co-Founder notifies of intention to sell stock Jun 25
Co-Founder notifies of intention to sell stock May 20
Co-Founder & VP of Research notifies of intention to sell stock May 09
Insider notifies of intention to sell stock Apr 28
Co-Founder notifies of intention to sell stock Apr 27
High number of new directors Apr 27
Co-Founder notifies of intention to sell stock Apr 22
Vaxcyte, Inc., Annual General Meeting, Jun 01, 2022 Apr 21
Co-Founder & VP of Research notifies of intention to sell stock Apr 09
Vaxcyte, Inc. Announces Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in Adults Apr 06
President & CFO notifies of intention to sell stock Mar 24
Insider notifies of intention to sell stock Mar 15
Chief Operating Officer notifies of intention to sell stock Mar 01
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans Feb 25 주주 수익률 PCVX US Biotechs US 마켓 7D -7.6% 3.7% 5.7% 1Y 100.6% 29.2% 36.9%
전체 주주 수익률 보기
수익률 대 산업: PCVX 지난 1년 동안 29.2 %를 반환한 US Biotechs 산업을 초과했습니다.
수익률 대 시장: PCVX 지난 1년 동안 36.9 %를 반환한 US 시장을 초과했습니다.
가격 변동성 Is PCVX's price volatile compared to industry and market? PCVX volatility PCVX Average Weekly Movement 11.0% Biotechs Industry Average Movement 9.5% Market Average Movement 6.2% 10% most volatile stocks in US Market 15.3% 10% least volatile stocks in US Market 3.0%
안정적인 주가: PCVX 의 주가는 지난 3개월 동안 변동성이 심했습니다.
시간에 따른 변동성: PCVX 의 주간 변동성 ( 11% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.
회사 소개 임상 단계의 생명공학 백신 회사인 박사이츠는 세균성 전염병을 예방하거나 치료하기 위한 새로운 단백질 백신을 개발합니다. 주요 백신 후보는 침습성 폐렴구균 질환 예방을 위한 24가 폐렴구균 단백접합백신인 VAX-24입니다. 이 회사는 또한 신종 균주로부터 보호하고 항생제 내성 문제를 해결하기 위한 VAX-31, A군 연쇄상구균으로 인한 질병을 예방하기 위한 새로운 접합 백신 후보인 VAX-A1, 치주염을 일으키는 핵심 병원체를 표적으로 하는 새로운 단백질 백신 후보인 VAX-PG, 세균성 질환인 시겔라 예방을 위한 VAX-GI를 개발하고 있습니다.
자세히 보기 Vaxcyte, Inc. 기본 사항 요약 Vaxcyte 의 수익과 매출은 시가총액과 어떻게 비교하나요? PCVX 기본 통계 시가총액 US$12.92b 수익(TTM ) -US$507.65m 수익(TTM ) n/a
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) PCVX 손익 계산서(TTM ) 수익 US$0 수익 비용 US$75.00m 총 이익 -US$75.00m 기타 비용 US$432.65m 수익 -US$507.65m
주당 순이익(EPS) -4.07 총 마진 0.00% 순이익 마진 0.00% 부채/자본 비율 0%
PCVX 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}